The State is in compliance with the new drug review and utilization requirements set forth in section 1902(oo) of the Act, as follows:

1. Claim Review Requirements
   a. The following Safety Edits have been implemented at the Point-of-Sale including Early, Dosage, Duplicate, and Quantity Limits:
      i. The state has implemented the following prospective opioid safety edits:
         (1) Quantity limits, including days’ supply limits:
         (2) Length of therapy limits:
         (3) Refill frequency (percent to refill) limits;
         (4) Duplicate fills; and
         (5) Maximum MME/Day limits.
      ii. The state has implemented the following retrospective opioid safety reviews:
         (1) Quantity limits, including days’ supply limits;
         (2) Length of therapy limits;
         (3) Refill frequency (percent utilized to refill) limits;
         (4) Duplicate fills; and
         (5) Maximum MME/Day reviews.

2. Concurrent Utilization Alerts
   a. Opioid and Benzodiazepines Current Fill Reviews
      i. The state has implemented and monitors results of Point-of-Sale alerts for concomitant use of opioids and benzodiazepines.
   b. Opioid and Antipsychotic Concurrent Fill Reviews
      i. The state has implemented and monitors results of Point-of-Sale alerts for concomitant use of opioids and antipsychotics.
3. **Program to Monitor Antipsychotic Medication Use by Children**  
   a. The state has implemented and monitors the following:
      i. Age restrictions;
      ii. Quantity limits;
      iii. Prior authorization for duplicate therapy; and
      iv. Medication use in Foster Children.

4. **Fraud, Waste and Abuse Identification.**  
   a. The State has implemented policy requirements and monitors the results including but not limited to the following:
      i. Number of opioid prescribers per member;
      ii. Number of pharmacies utilized per member for opioid fills;
      iii. Prior authorization requirements for long acting opioids;
      iv. Controlled Substances Prescription Monitoring Program, the State’s PDMP, review for all prior authorization requests for opioids; and
      v. Controlled and Non-Controlled Utilization including the following:
          1. Atypical Antipsychotics;
          2. Benzodiazepines;
          3. Hypnotics;
          4. Muscle Relaxants;
          5. Opioids
          6. Stimulants; and
          7. Others as identified.